Abstract: Metabolic syndrome (MetS) is a clinical syndrome characterized by the clustering of central obesity, abnormalities in glucose and lipid metabolism, and hypertension.Endoscopic bariatric interventions are distinguished by minimal invasiveness, reversibility, and a low complication profile, and have been rapidly adopted in clinical practice in China in recent years.The domestically developed gastric bypass stent, approved in 2024 as the first marketed endoscopic bariatric device in China, has seen rapid clinical expansion; however, its own evidence base is still being established.Endo Barrier, a device based on the same principle, has accumulated multi-level evidence—including multicenter randomized controlled trials and national registries—and its experience regarding evolving clinical positioning, efficacy divergence, safety governance, implantation duration, and baseline population characteristics offers important reference value for the domestic stent.Drawing on more than a decade of evidence-based experience with Endo Barrier and integrating the latest full-text data from domestic multicenter randomized controlled trials, real-world cohorts, and randomized studies, this article systematically reviews the efficacy, clinical positioning, implantation duration, and safety management of the domestic gastric bypass stent.

Key words: metabolic syndrome; gastric bypass stent; duodenal-jejunal bypass liner (DJBL); real-world study